Observation of the effect of cinobufacini injection in the treatment of mid and advanced primary bronchopulmonary carcinoma
10.3760/cma.j.issn.1008-6706.2014.13.004
- VernacularTitle:华蟾素治疗中晚期肺癌的疗效观察
- Author:
Juan ZHOU
;
Xueming YUAN
;
Gengjie WANG
;
Bin YU
;
Zhan CHEN
- Publication Type:Journal Article
- Keywords:
Cinobufacini injection;
Lung neoplasms
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;21(13):1929-1930
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical curative effect of cinobufacini injection in the treatment of primary bronchopulmonary carcinoma.Methods 120 patients with primary bronchopulmonary carcinoma were randomly divided into the control group and treatment group,60 cases in each group.Patients of the control group were treated with the general,symptomatic and dialectical therapy.Patients of the treatment group were given general,symptomatic,dialectical treatment and cinobufacini injection.The curative effect was determined by the standard efficacy of tumor,the survival quality of the patients was judged by the Karnofsky score.The adverse reactions,median survival time and the survival rate were compared between the two groups.Results The effective rate of the control group was 40.0％,that of the treatment group was 56.7％,the difference was statistically significant (x2 =4.034,P ＜ 0.05).By the Karnofsky score,27 patients of the control group were stable,39 patients of the treatment group were stable,the difference was statistically significant(x2 =12.265,P ＜0.05).Median survival time of the control group was (168 ± 16) d,that of the treatment group was (178 ± 20)d,the difference was statistically significant(x2 =12.265,P ＜ 0.05).One year survival rates of the control group and the treatment group were 5.0％,10.0％,the difference was statistically significant.There was no statistically significant difference between two groups in adverse reactions (P ＞ 0.05).Conclusion Cinobufacini injection can improve the quality of life and prolong survival of patients with primary bronchopulmonary carcinoma.It is effective and safe in clinical application.
